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BACKGROUND: Cancer is a risk factor for venous thromboembolism (VTE). Circulating tumour cells (CTCs) are an independent
predictor of survival in metastatic breast cancer (MBC) patients. The aim of this study was to test the hypothesis that CTCs are
associated with the risk of VTE in MBC patients.
METHODS: This retrospective study included 290 MBC patients treated in the MD Anderson Cancer Center from January 2004 to
December 2007. Circulating tumour cells were detected and enumerated using the CellSearch system before starting new lines of
therapy.
RESULTS: At a median follow-up of 12.5 months, 25 patients experienced VTE and 53 patients died without experiencing thrombosis.
Cumulative incidence of thrombosis at 12 months was 8.5% (95% confidence interval (CI)¼5.5%, 12.4%). Patients with CTCs X1
and X5 had a higher incidence of VTE compared with patients with 0 and o5 CTCs (12-month estimate, 11.7 and 11.6% vs 3 and
6.6%; P¼0.006 and P¼0.076, respectively). In the multivariate model, patients with CTCsX1 had a hazard ratio of VTE of 5.29
(95% CI¼1.58, 17.7, P¼0.007) compared with patients with no CTCs.
CONCLUSION: These results suggest that CTCs in MBC patients are associated with increased risk of VTE. These patients should be
followed up more closely for the risk of VTE.
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Cancer is a well-recognised risk factor for venous thromboembo-
lism (VTE). It has been shown that 5–10% of all cancer patients
will develop VTE during the course of the disease (Silverstein et al,
1998). Evidence suggests that the absolute risk depends on the
tumour type, the stage or extent of the cancer, and treatment with
antineoplastic agents (Silverstein et al, 1998).
Venous thromboembolism following breast cancer chemo-
therapy is common. In early breast cancer, VTE occurs in 5–
10% of patients receiving chemotherapy (Weiss et al, 1981; Levine
et al, 1988; von Tempelhoff et al, 1996), and it rises up to 18% in
advanced breast cancer with 9% mortality (Goodnough et al, 1984;
Kirwan et al, 2008).
Circulating tumour cells (CTCs) are an independent predictor
of progression-free survival (PFS) and overall survival (OS) in
patients with metastatic breast cancer (MBC) (Cristofanilli et al,
2004). Superior survival among patients with o5 CTCs was
observed regardless of histology, hormone receptor and HER2/neu
status, sites of first metastases, or whether the patient had relapse
or de novo metastatic disease (Cristofanilli et al, 2004; Dawood
et al, 2008).
Increased CTC count and VTE are poor prognostic factors in
MBC and are linked to inferior survival. In this retrospective study,
we tested the hypothesis that CTCs are associated with the risk of
VTE in MBC patients.
PATIENTS AND METHODS
Study patients
This study was conducted using the MD Anderson Cancer Center
medical records database. The retrospective study was approved
by the institutional review board and a waiver of consent form was
granted. A population of consecutive MBC patients with at least
one measurement of CTC before starting a new line of therapy
from January 2004 to December 2007 was eligible. In addition,
patients were not excluded on the basis of whether they underwent
treatment with any particular form of chemotherapy, hormonal
therapy, or biological therapy. Patients on prophylactic or
therapeutic anticoagulation therapy including warfarin 1mg per
day or equivalent for port-a-catheter thromboprophylaxis, low
molecular weight heparin, or unfractionated heparin were
excluded from the analysis. Patients with concurrent malignancy
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sother than non-melanoma skin cancer in the previous 5 years
were excluded as well. In all, patient data regarding age, tumour
histology, hormone receptor status, HER2 status, type and number
of metastatic sites, systemic therapy, history of VTE, comorbidities
(hypertension, diabetes mellitus), and concomitant therapy were
also recorded and compared with risk of VTE.
Definition of the events
All venous thrombosis and/or pulmonary embolism in the
presence of unequivocal medical documentation were classified
as events. A patient was considered to have had a VTE if the event
was clinically apparent and confirmed by diagnostic studies. Cases
of superficial phlebitis and cases of secondary thrombosis
attributed to superior vena cava syndrome and/or bulky abdom-
inal lymphadenopathy were not classified as events and were
excluded from the analysis.
Detection of CTCs in peripheral blood
The CellSearch system (Veridex Corporation, Warren, NJ, USA)
was used to detect CTCs in 7.5ml of whole peripheral blood.
Samples were subject to enrichment with anti-EpCAM-coated
beads. Circulating tumour cells were defined as nucleated cells
lacking CD45 but expressing cytokeratines 8, 18, or 19.
Statistical analysis
Baseline CTCs were defined as the earliest CTC measurement taken
before the start of a new line of therapy. Time to thrombosis was
calculated from the date of baseline CTC assessment to the date of
thrombosis or last follow-up. We calculated the cumulative
incidence of thrombosis according to the method previously
described (Gray, 1988). We considered baseline CTCs as a
continuous measurement, dichotomised at 1 and at 5. The cutoff
at 1 was chosen because it has been investigated in other settings
such as primary breast cancer (Cristofanilli et al, 2004; Lang et al,
2009). The cutoff at 5 has been established as prognostic for PFS
and OS for MBC patients in other studies.
Analyses were repeated considering patients who died before
experiencing a thrombosis as censored at their date of death and
estimating survival from thrombosis according to the Kaplan–
Meier method. Results were similar. Therefore, we used Cox
proportional hazards models both to assess CTCs as continuous
measurements and to determine the association between CTCs and
thrombosis after adjustment for other patient and disease
characteristics.
Analyses were conducted in R2.4.0 with the contributed
package, cmprsk (Gray, 2004; R Development Core Team, 2006).
P-values o0.05 were considered statistically significant.
RESULTS
We identified 290 patients who satisfied the study eligibility
criteria and were included in this analysis. Patient characteristics
are shown in Table 1.
A total of 25 patients experienced a thrombosis and 53 patients
died without experiencing a thrombosis. Estimates of the
cumulative incidence of thrombosis are shown in Table 2. Among
all patients, the cumulative incidence of thrombosis at 12 months
was 8.5% (95% confidence interval (CI)¼5.5%, 12.4%). There was
no association between baseline CTCs and thrombosis when
baseline CTCs were considered as continuous in a univariate Cox
proportional hazards model (hazards ratio (HR)¼1.0, 95%
CI¼0.994, 1.00, P¼0.73). When baseline CTCs were considered
dichotomised at 1, patients with CTCsX1 had four times higher
incidence of thrombosis compared with patients with CTC¼0
(12-month estimate 3.0 vs 11.7%, P¼0.006). Patients with
CTCsX1 have inferior survival compared with patients with
CTC¼0 (HR¼0.54, 95% CI¼0.33–0.89, P¼0.03). When patients
were considered grouped according to CTCsX5 vs CTCso5,
patients with fewer CTCs had a lower incidence of thrombosis
compared with patients with more CTCs; however, statistical
significance was not attained (6.6 vs 11.6%, P¼0.076).
We considered the baseline CTC measurement dichotomised as
0 vs 1 or more in a multivariable Cox proportional hazards model
Table 1 Patient characteristics (n¼290)
N Percent
Median age; years (range) 54 (23–84)
Median baseline CTC (range) 2 (0–1780)
Line of therapy
1 123 42.41
2 or more 167 57.59
Estrogen and progesteron receptor
Positive for both 192 66.21
Negative for either 98 33.79
HER2/neu amplified
No 227 78.28
Yes 62 21.38
Unknown 1 0.34
Inflammatory breast cancer
No 222 76.55
Yes 68 23.45
Visceral metastasis
No 109 37.59
Yes 181 62.41
Bone metastasis
No 88 30.34
Yes 202 69.66
Number of sites of metastasis
1 100 34.48
2 89 30.69
3 55 18.97
X4 46 15.86
Chemotherapy
No 36 12.41
Yes 254 87.59
Bevacizumab-based therapy 60 20.69
Hormonal therapy
No 164 56.55
Yes 126 43.45
Erythropoietin-stimulating agents
No 256 88.28
Yes 34 11.72
Port-a-catheter and/or central venous device
No 211 72.76
Yes 79 27.24
Arterial hypertension
No 188 64.83
Yes 102 35.17
Diabetes mellitus
No 255 87.93
Yes 35 12.07
Abbreviation: CTC¼circulating tumour cells.
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sto determine whether the association with thrombosis persisted
after adjustment for other characteristics After adjustment for
these other terms, having at least one CTC was associated with 5.29
times the risk of thrombosis compared with patients with no CTC
(95% CI¼1.58, 17.7, P¼0.007) (Table 3).
DISCUSSION
This large single centre retrospective study showed that CTCs are
associated with increased risk of VTE in MBC patients. The risk is
increased in patients with CTCsX1 before starting new line of
therapy. Observed cumulative 12-month incidence of VTE in our
patients was 8.5%, which is in concordance with data from
literature. (Ottinger et al, 1995; Baron et al, 1998). We confirmed
that the presence of visceral metastases, increased number of
metastases, and subsequent lines of therapy are associated with
increased risk of VTE. These factors mainly reflect advanced
disease, with higher incidence of VTE at all.
In a prospective, multicentre study, the number of CTCs before
chemotherapy was an independent predictor of PFS and OS in
MBC patients. Although the threshold of 5 CTCs per 7.5ml of
blood has been shown to be prognostic for survival (Cristofanilli
et al, 2004), in our study, any detectable CTCs were associated with
increased risk for VTE as well as with increased risk of death. We
also observed that MBC patients with CTCsX5 have a doubled risk
of VTE compared with patients with CTCso5; however, this
difference did not reach statistical significance.
There are several mechanisms that may explain this association
(CTC and VTE). Increased CTC count is a marker of more
aggressive disease with increased risk of VTE (Cristofanilli et al,
2004). Circulating tumour cells could be directly involved in
coagulation activation as well. It is supposed that the direct toxic
effect of anticancer treatment on cancer cells may lead to an
increase in CTC fragments or microparticles with procoagulant
activity (Dvorak et al, 1983). Circulating tumour cells could be
involved in the activation of coagulation through the expression
and release of tissue factors (TFs) (Davila et al, 2008). It was shown
that TFs are overexpressed in cells with cancer stem cell phenotype
(Milsom et al, 2007). At least the subgroups of CTCs are potential
cancer stem cells (Reuben et al, 2007); therefore, CTCs could be an
important source of TFs and could be involved directly in
coagulation activation.
The main limitation of this trial is the retrospective nature
of analysis. Therefore, the study results are only hypothesis
Table 2 Estimates of the cumulative incidence of thrombosis
N
No of
thrombosis
events
12-Month
estimate
(percent)
95%
Confidence
interval P-value
All 290 25 8.5 (5.5, 12.4) —
Baseline CTC
0 108 3 3.0 (0.8, 7.9)
X1 182 22 11.7 (7.3, 17.3) 0.006
Baseline CTC
o5 177 11 6.6 (3.3, 11.4)
X5 113 14 11.6 (6.3, 18.6) 0.076
Age (years)
o50 100 10 8.9 (4.1, 15.9)
450 190 15 8.3 (4.7, 13.2) 0.552
Line of therapy
1 123 6 3.3 (1.1, 7.8)
X2 167 19 12.8 (7.8, 19.1) 0.027
Estrogen and progesteron receptor
Positive for both 192 14 6.4 (3.4, 10.8)
Negative for either 98 11 12.8 (6.7, 21.0) 0.188
HER2/neu amplified
No 227 20 8.4 (5.1, 12.8)
Yes 62 5 8.8 (3.2, 18.1) 0.900
Inflammatory breast cancer
No 222 17 7.9 (4.7, 12.1)
Yes 68 8 11.1 (4.3, 21.3) 0.234
Visceral metastasis
No 109 2 2.0 (0.4, 6.3)
Yes 181 23 12.3 (7.8, 18.0) 0.002
Bone metastasis
No 88 6 8.6 (3.4, 16.9)
Yes 202 19 8.6 (5.1, 13.2) 0.547
Number of sites of metastasis
1 100 3 3.53 (0.9, 9.2)
2 or 3 144 11 7.69 (3.9, 13.2)
X4 46 11 21.07 (10.2, 34.5) 0.002
Chemotherapy
No 36 3 5.6 (1.0, 16.5)
Yes 254 22 8.8 (5.6, 13.0) 0.934
Bevacizumab-based therapy
No 230 20 8.1 (4.9, 12.4)
Yes 60 5 10.0 (3.5, 20.5) 0.999
Hormonal therapy
No 164 19 11.9 (7.2, 18.0)
Yes 126 6 4.2 (1.6, 8.9) 0.037
Tamoxifen
No 101 10 10.4 (5.3, 17.5)
Yes 38 1 0.0 — 0.177
Aromatase inhibitors
No 194 22 11.2 (7.0, 16.6)
Yes 96 3 3.2 (0.9, 8.3) 0.016
Erythropoetin-stimulating agents
No 256 24 9.3 (5.9, 13.6)
Yes 34 1 2.9 (0.2, 13.2) 0.150
Table 2 (Continued)
N
No of
thrombosis
events
12-Month
estimate
(percent)
95%
Confidence
interval P-value
Port-a-catheter and/or central venous device
No 211 17 7.9 (4.6, 12.4)
Yes 79 8 9.8 (4.2, 18.1) 0.747
History of DVT/PE
No 274 23 8.0 (5.1, 11.9)
Yes 16 2 14.6 (2.0, 38.7) 0.672
Arterial hypertension
No 188 19 9.1 (5.4, 13.9)
Yes 102 6 7.5 (3.0, 14.8) 0.242
Diabetes mellitus
No 255 22 8.5 (5.3, 12.6)
Yes 35 3 8.9 (2.2, 21.6) 0.924
Abbreviations: DVT¼deep vein thrombosis; PE¼ pulmonary embolism, CTC¼
circulating tumour cells.
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sgenerating. Sample size, heterogeneous patient population, and
heterogenity of therapy might affect the study results. On the other
hand, the majority of patients in our analysis were treated
according to daily clinical practice, which might increase the
generalisability of the results.
To our knowledge, this is the first study to assess the prognostic
value of CTCs on the risk of VTE. Patients with MBC and any
detectable CTCs are at increased risk for VTE. These patients
should be followed more closely for the risk of VTE. Further
research in this field is warranted, with prospective assessment of
coagulation status and its correlation with CTC count and clinical
outcome.
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